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Introduction
Cancer of the breast in women is a major health burden
worldwide. It is the most common cause of cancer among
women in both high-resource and low-resource settings,
and is responsible for over one million of the estimated
10 million neoplasms diagnosed worldwide each year in
both sexes [1]. It is also the primary cause of cancer death
among women globally, responsible for about 375,000
deaths in the year 2000 [1].
International comparisons of disease rates by area and
time of diagnosis can provide important clues to the
underlying causes of diseases and the effects of natural or
planned interventions, and serve as indicators of the
scope for preventive strategies. There is at least a 10-fold
variation in breast cancer incidence rates worldwide [2],
largely as a consequence of a range of socio-economically
correlated differences in the population prevalence of
several reproductive, hormonal and nutritional factors. In
some high-resource countries, mammographic screening
has considerably affected breast cancer diagnosis,
registration and mortality.
Studies of migrants provided the first solid evidence that
environmental (rather than genetic) determinants were
responsible for most of the observed international and
inter-ethnic differences in breast cancer incidence:
comparisons of breast cancer risk in (low-risk) Asian
populations migrating to the (high-risk) USA and their
offspring revealed major increases in risk between
successive generations [3], and increases in risk were
observed in populations from European countries with
relatively low incidence (Italy and Poland) after migration
to Australia, particularly if the migration took place in
childhood [4,5].
As a consequence of changing exposures to reproductive
and nutrition-related determinants over time, women are at
increasingly high risk of breast cancer, with incidence
rates increasing in most countries and regions of the
world in the past few decades. The most rapid rises are
seen in developing countries, where breast cancer risk
has historically been low relative to industrialised
countries. Increasing trends in developing areas are often
considered the result of the ‘westernisation’ of lifestyles,
an ill-defined surrogate for changes in factors such as
childbearing, dietary habits and exposure to exogenous
oestrogen, towards a distribution closer in profile to that of
women in industrialised countries.
The variations in mortality reflect, in part, variations in
incidence (and its determinants), but mortality is also
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influenced by case-fatality. It is therefore affected by early
diagnosis (another correlate of socio-economic status),
either through screening or as a result of increasing
individual awareness of the disease and its symptoms. In
high-resource to medium-resource settings, advances in
breast cancer therapy in recent years have made a
considerable contribution to improved survival and the
subsequent reduction or stabilisation of breast cancer
death rates.
In this paper we review the descriptive epidemiology of
the disease, focusing on some of the key elements of the
geographical and temporal variations in incidence and
mortality in each region of the world. The review includes
published studies and some new analyses using incidence
data from population-based cancer registries and mortality
data from the WHO databank. We then discuss possible
explanations for the results in the light of the changing
prevalence of the known aetiological factors, the impact of
screening and other preventive strategies, and progress in
disease management; we conclude with some comments
on future prospects for prevention.
Geographical variations worldwide
Worldwide, more than one million new cases of female
breast cancer are diagnosed each year. It is the most
commonly occurring neoplasm in women, accounting for
over one-fifth of the estimated annual 4.7 million cancer
diagnoses in females, and the second most common
tumour, after lung cancer, in both sexes [1]. It is also the
most common female cancer in both developing and
developed countries, with most (55%) occurring in the
latter regions, where age-standardised rates are three
times higher than in developing areas [1].
The estimated number of deaths from female breast
cancer in 2000 is considerably lower – about 375,000
deaths – reflecting the reasonably good overall survival.
Prognosis is heavily dependant on stage of disease at
presentation, however. In the Surveillance, Epidemiology,
and End Results (SEER) registries in the USA, 5-year
survival for localised cases in 1994 was about 97% but
was only about 25% for cases with metastatic disease [6].
In developing countries, the differences in survival by
stage at diagnosis are also very marked [7]. In Europe, 5-
year relative survival rates vary from 83% in Sweden to
61% in Slovakia [8], and although trends show clear
improvement over time, the utility of survival in monitoring
patient outcome has been questioned in countries
affected by artefactual increases in registrations due to
screening [9].
Figure 1 shows the geographical variation in breast
cancer incidence worldwide, as estimated for the year
2000. The highest incidence rates occur in northern and
western Europe, northern America, Australia and New
Zealand, and in southern countries of South America,
notably Uruguay and Argentina. Clear geographical
differences in risk are apparent within Europe, with
elevated rates in northern and western Europe, whereas
rates in most southern and eastern European countries
are low to intermediate [10]. Incidence is low throughout
Africa, Asia and most of Central and South America
(Fig. 1). The corresponding map of breast cancer
mortality conveys a similar picture. To highlight the
international variability in risk of breast cancer incidence,
Fig. 2 shows the age-standardised (world) incidence
rates in selected populations based on cancer registry
data from 1993 to 1997 compiled in the latest volume
(volume VIII) of Cancer Incidence in Five Continents [2].
Rates of more than 100 per 100,000 are noted in
several US states, whereas the highest rates are
recorded in Montevideo in Uruguay (Fig. 2). Rates are
elevated (50–100 per 100,000) in registries in
geographically diverse areas of the world including most
northern and western European countries, Canada,
Israel and Argentina. US-born Filipinos and Hawaiian-
born Chinese also have high rates (Fig. 2). In several
Asian populations, including those in Hong Kong,
Singapore (Chinese) and the Philippines (Manilla), rates
are intermediate (30–50 per 100,000), as they are in
Puerto Rico and Goiania (Brazil) in South America, and
most eastern European populations (Fig. 2). The lowest
rates are seen in several Chinese populations including
the Quidong registry, with breast cancer incidence rates
of about 10 per 100,000, whereas observed rates are
also low (10–30 per 100,000) in eastern African
populations in Zimbabwe and Uganda, Algiers in North
Africa, several South-East Asian registries (Thailand and
Vietnam), and several registries in India (Fig. 2). Koreans
living in the USA have retained a relatively low breast
cancer incidence rate (about 28 per 100,000) not
dissimilar to that of Koreans living in Korea (21 per
100,000 in Seoul), in comparison with the high rates
now seen in other US-born races of Asian descent,
notably Filipinos (Fig. 2).
Age-specific variations worldwide
Breast cancer incidence has a distinctive age-specific
curve (Fig. 3). The rapid rate of increase before the
menopause (ages 40–50) slows down after that, probably
owing to diminishing levels of circulating oestrogens [11].
In low-incidence countries, the slope of the curve after the
menopause may be flat, or even negative (for example in
Khon Kaen in Fig. 3). This is a consequence of increasing
risks of occurrence in consecutive generations of women
rather than a real decline in risk with age [12]. The young
age structure of populations in developing countries
coupled with a rather flat age-incidence curve (Fig. 3)
implies that the mean age at diagnosis in developing
countries is lower than that of European and American
populations.
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Patterns of breast cancer by world region
The changing profile of breast cancer incidence and
mortality between populations in each region, and within
populations over time, is reviewed below, on the basis of
the relevant published literature and with reference to
Fig. 4, which shows time trends of overall incidence for
selected countries in the Americas, in Asia/Oceania and in
Europe, to Fig. 5, which contrasts the percentage change
in mortality rates between 1985–87 and 1995–97 in
selected countries worldwide, and to Figs 6–8, which
show incidence and mortality trends in selected European
populations based on data compiled in the EUROCIM
database [13].
Europe
Trends in incidence
In countries where national screening programmes started
in the mid- to late 1980s (the Nordic countries, England
and Wales and The Netherlands), incidence rates were
increasing before organised screening activity [14] (for
example A and B in Fig. 4). Mean annual increments of
1–3% were observed, with the largest increases being in
Finland and The Netherlands (Eindhoven) [14]. Neither of
these populations witnessed a screening-related increase
[14,15] – a short-term upsurge in incidence within
screened age groups due to the detection of prevalent
cancers during the first screening round – as observed in
England and Wales [16] and Sweden [17] (Fig. 6a). Quite
substantial increases in incidence up to the mid-1990s –
greater than 2% per year – were also seen in several
countries that either had not introduced programmes, had
implemented them very recently or had regional or pilot
programmes under way (for example C and D in Fig. 4). In
Norway, the annual increase was slightly less (1.6%) but
the introduction of breast screening in 1996, covering
40% of the population [18], resulted in an upsurge in
incidence [19]. Increases of between 2% and 4% in
breast cancer incidence per year have been reported in six
former-USSR regions between 1971 and 1987 [20].
In most countries, the upward trend in incidence occurred
across the age groups 35–49, 50–64 and 65–74 years
[14], and as a result, attributing the time trend to period
and cohort influences is difficult, although in studies that
Available online http://breast-cancer-research.com/content/6/6/229
Figure 1
Breast cancer incidence worldwide: age-standardised rates (world population). Source: [1].
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have examined unscreened women, or have adjusted for
screening effects, cohort effects are evident in Denmark
[21–23], Norway [24] and Sweden [25].
The most recent data indicate some signs of a plateau in
incident trends in several countries during the mid-1990s,
particularly in The Netherlands, in Sweden and in England
and Wales [14]. This has been speculated to be a result
of a cohort-specific peak in incidence [15], although the
observations are also consistent with what would be
expected after the initial breast screening round: a decline
after the post-screening increase to a level slightly higher
than that before screening [26].
Trends in mortality
Mortality in most countries has increased from the 1950s
until at least the 1980s, particularly in eastern and
southern countries of Europe. A levelling off and
subsequent decline in breast cancer mortality from the
early 1990s became evident in England and Wales
[9,27,28] and The Netherlands [27] and has now also
been observed in several other European countries [14],
although the declines are often confined to women aged
less than 50 years (Fig. 5).
The pattern in Sweden is unusual because a rather stable
or slowly declining trend, notably in middle-aged and
elderly women, has been observed since the 1960s [29],
and declines are evident in all age groups at least since
the late 1980s (Fig. 6b). In Denmark, both incidence
(Fig. 7a) and mortality (Fig. 7b) are declining in young
women, and strong cohort effects are observed, with
decreasing rates in women born in successive
generations after 1940 (Fig. 7c). In Finland, such a
reduction in mortality rates has not occurred (Fig. 5).
Some recent decreases in mortality are observed in
several countries without national screening programmes,
although these tend to be confined mainly to younger age
groups (Fig. 5). Mortality is increasing in several eastern
European or former Soviet countries, characterised by
relatively low rates in the past, such as the Russian
Federation (Fig. 5), Estonia (Fig. 8b, showing similar
trends to incidence in Fig. 8a), Romania (Fig. 8c) and
Hungary (Fig. 8d).
North America
Trends in incidence
The pattern observed in the USA and Canada is broadly
similar to that of Europe, with similar increases in
incidence in both white and black women [30] (E–G in
Fig. 4). Most of this increase occurred in the period
between 1980 and 1987 [6] and is related to rises in
Breast Cancer Research    Vol 6 No 6 Bray et al.
Figure 2
Variations in breast cancer incidence in selected cancer registries:
age-standardised rates (world population). Source: [2].
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Figure 3
Age-specific breast cancer incidence rates in selected cancer
registries. Source: [2].
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mammography-detected incident cases as a result of the
intensification of breast screening at this time [31]. The
overall rate of increase has slowed to 0.6% per year since
the late 1980s [32]. Early studies of Connecticut
incidence data, before widespread mammography
emerged, had commented on the importance of birth
cohort effects [21]. A proposition that incidence rates of
breast cancer were levelling off in women born after 1925
[33] has been almost impossible to follow up in the light of
the effects of subsequent screening on incidence.
Trends in mortality
The levelling off in mortality and subsequent decline that
took place in several northern European countries in the
1980s was also noted in both the USA [34] and Canada
[35], and the extent of the decrease in both younger and
older women is shown in Fig. 5. Although the trends were
similar from the 1970s through to the mid-1980s in both
US whites and blacks, they diverged thereafter, with white
women experiencing a levelling off and subsequent
decline in mortality from the early 1990s, whereas in
contrast mortality increased slightly in black women
throughout the period [30]. From 1992 to 2000, breast
cancer death rates among white women declined in 38
US states, whereas among blacks increases were
observed in several states [32].
There have been several studies examining calendar
period and birth components of the mortality trends
[36,37]. A decline in breast cancer rates among women
born after about 1920 has been reported in Canada and
in the USA among both blacks and whites. Birth cohort
trends for all women were similar until about 1940, with a
moderation of mortality risk beginning in about 1924. A
marked moderation of risk by birth cohort was observed
for US white women born after 1950, whereas stable or
slightly decreasing trends were observed for US black
women and Canadian women. The slope of the mortality
trend by calendar period increased in the 1980s
compared with the 1970s for all women. In the last
calendar period, in the early 1990s, a trend of decreasing
mortality rates was found for US white and Canadian
women [37].
Australia and New Zealand
Incidence of breast cancer in New South Wales
(representing about one-third of Australian women)
increased steadily from the early to mid-1980s (J in Fig. 4),
and by 1995 was nearly 50% higher than in 1983. The
greatest increase was in the target age group for
mammographic screening (50–69 years), which became
available from 1984 on a limited basis and in 1992 was
nationwide and accessible to all women aged at least
Available online http://breast-cancer-research.com/content/6/6/229
Figure 4
Breast cancer incidence trends over time in selected cancer registries in Europe, the Americas and Asia: age-standardised rates (world
population). Source: [2].
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40 years [38]. In New Zealand there were steady
increases in both Maori and non-Maori incidence rates
from 1978–92 [39].
Breast cancer mortality in Australia rose steadily from the
early 1970s to the late 1980s [40]. Between 1985–1989
and 1990–1994, breast cancer mortality fell by 3.2% in
women 50–69 years of age and by 4.2% in 25–49-year-
olds, with little change (–0.2%) in breast cancer mortality
in older women in this period [40]. The proportion of
women screened in all age groups increased substantially
between 1988 and 1994, and by 1994 nearly 65% of
women in the target age group had had at least one
mammogram [40]. Cohort-specific mortality has been
reported to be rather uniform [41], particularly in young
women [40].
Japan
Although breast cancer remains relatively rare in Japan,
incidence (K in Fig. 4) and mortality (Fig. 5) have been
rising quite rapidly, which is consistent with increasing risk
in successive generations of women [42]. The overall
incidence has been increasing since the mid-1970s
[42,43] although the increase has been much larger than
for mortality, demonstrating improving prognosis over time
[42]. In more recent epochs, accelerating increases in the
incidence rates have been attributed to both period and
cohort effects [43,44].
Developing countries
There is a paucity of sufficiently long time series of high-
quality cancer data in many developing areas at the
present time, but nonetheless, where they are available,
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Figure 5
Percentage change in breast cancer mortality between 1985–87 and 1995–97 in women aged 50–74 and 25–49 years in selected countries
worldwide, sorted by descending order of magnitude of the change (earlier period is 1988–90 for China, later period is 1994–96 for Argentina).
Source: http://www-depdb.iarc.fr/who/menu.htm.
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increases in breast cancer incidence and mortality are
seen, an observation often more apparent within recent
birth cohorts [45], and a probable consequence of the
adoption of western lifestyles [46].
Latin America
Most countries have intermediate rates of breast cancer
occurrence. Incidence and mortality rates have been
observed to be increasing in most countries [46];
incidence has at least doubled, for instance, in Cali,
Colombia, and in Puerto Rico (H and I in Fig. 5) between
the early 1970s and the mid-1990s. In Uruguay, Argentina
and Chile, women are at high or intermediate risk, and
mortality rates in younger women have been reported to
be more or less constant over time [45].
Asia
Age-adjusted incidence is low in most countries, although
rates are more than 50 per 100,000 (world standardised
rate) in Manila in the Philippines and South Karachi in
Pakistan. Rates in Singapore, particularly among the
Chinese, are also relatively high for the region. Studies
comparing the risks in migrants to the USA and their
offspring born there have revealed substantial increases in
risk between first, second and third generations. Rising
incidence has been observed in India [47] and also in
Singapore, where there were average annual increases of
3.6% between 1968 and 1992, attributed mainly to birth
cohort effects [48]. The extent of the mean annual rate of
increase in Singapore, as reported in the latter study,
ranged from 4.4% in Malays to 1.4% in Indians [48]. In
China, mortality increased over the period 1987–99 in
both rural and urban areas, the change being more evident
in rural areas although the rates have remained lower than
in urban females [49]. The twofold increase in mortality in
Taiwan between the 1960s and 1990s has been
attributed to both period and cohort influences [50],
whereas in Hong Kong increases of the same order of
magnitude were considered to be primarily the result of
cohort effects [51].
Africa
Although breast cancer is the most common neoplasm
among women in developing countries, if Africa is taken as
a whole it ranks second most frequent to cervical cancer
[1]. However, it is the most common malignancy in North
Africa and in urban settings within the sub-Saharan region
such as Abidjan (Côte d’Ivoire) [52], and until recently
also in Harare, Zimbabwe, although changes in the
evolution of the AIDS epidemic have led to its now having
been overtaken by Kaposi’s sarcoma [53]. In the few
datasets available for the study of time trends in Africa,
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Figure 6
Incidence (a) and mortality trends (b) by age group in Sweden:
truncated age-standardised rate (European population). Source: [13].
Figure 7
Incidence (a) and mortality trends (b) by age group in Denmark:
truncated age-standardised rate (European population). (c) Breast
cancer age-specific mortality by birth cohort, age-cohort model
parameters for the same dataset. Source: [13].
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increases in incidence, for example, are apparent [45].
There have been twofold increases in breast cancer
incidence in Ibadan, Nigeria [54], and in Kampala, Uganda
[55], between the 1960s and the late 1990s. Steady
increases in breast cancer mortality rates of the same
order of magnitude have also been noted from the early
1960s in Mauritius [54].
Explaining geographical and temporal
variations in breast cancer
The changes in breast cancer incidence and mortality over
time seem complex, although broadly speaking the largest
increases in risk have been seen in populations of women
historically at lowest risk, often within developing
countries, whereas relatively recent departures from the
long-term trend have been observed in several, mainly
western, countries.
Risk factors
In general, the high rates of breast cancer in developed
countries are the consequence of a higher prevalence of
the known risk factors for the disease, many of which –
early age at menarche, nulliparity, late age at first birth, late
age at any birth, low parity, and late menopause – relate to
the hormonal (largely oestrogen) milieu to which the
breast is exposed from menarche to the cessation of
ovulation at menopause [56]. The higher parity and earlier
age at first pregnancy of women seen in many developing
countries might account for much of the lower incidence
of breast cancer in these regions relative to developed
countries. The long-standing hypothesis that breast-
feeding of longer duration is protective [57] has been
affirmed again recently [58].
The association between socio-economic status and risk
of breast cancer is well established, with women in higher
socio-economic groupings being at higher risk. When
social class is measured by income or education level, the
variations in risk largely accord with the differential
distribution of known risk factors, as observed in the USA
[59]. The greater risk for women from affluent back-
grounds is, however, outweighed by their lower mortality,
women from deprived backgrounds often presenting with
more advanced disease [60].
Exposure to exogenous hormones as oral contraceptives
[61] and hormone replacement therapy [58] result in an
increase in the risk of breast cancer. The risk conferred by
oral contraceptive use is, however, rather small and although
it persists for up to 10 years after cessation, cancers in these
women, as with women taking hormone replacement
therapy, are usually not clinically advanced at presentation,
thus rendering the impact on mortality rather modest.
Although there is a long-established correlation between
the incidence of breast cancer and dietary fat intake in
populations [62], the true relation between fat intake and
breast cancer does not seem to be particularly strong or
consistent [63,64]. The effect of large weight gains after
the age of 18 has been shown to be a strong risk factor
for breast cancer in postmenopausal women [65], with
risk increasing by 2% per unit body mass index [66].
Excessive alcohol intake also seems to increase risk, with
a recent re-analysis of 53 studies indicating that about 4%
of breast cancers in developed countries might be
attributable to its consumption [67].
The changing patterns of childbearing and breastfeeding,
of exogenous hormonal intake and of dietary factors
including obesity and reduced physical activity have
certainly contributed to trends in incidence and mortality.
Pinpointing the particular factors that have contributed in
different populations worldwide has proved a major
challenge, and the underlying reasons are certain to be
Breast Cancer Research    Vol 6 No 6 Bray et al.
Figure 8
Incidence (a) and mortality trends (b) by age group in Estonia;
mortality trends by age group in Romania (c); mortality trends by age
group in Hungary (d): truncated age-standardised rate (European
population). Source: [13].
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multiple and interactive. The accompanying evidence on
exposure to endogenous and exogenous oestrogen
indicates that the lifetime length of exposure to
endogenous oestrogen has been increasing, which is
consistent with upward trends in incidence of breast
cancer, particularly in developed countries.
Early detection and mammographic screening
Mammographic screening for women aged 50–69 years
is effective in reducing breast cancer mortality, and
reductions in mortality have been observed where
screening has been introduced [68,69]. Evidence that at
least part of this decline can be attributed to screening
comes from the expected increase in incidence of early
stage and in situ breast cancers, followed by a decline in
advanced cancer and subsequent mortality in the UK,
northern Europe and Australia [70–73]. It has been
estimated that about one-third of the overall 21%
reduction in breast cancer mortality in the UK by 1998
(10 years after screening began) was due directly to
screening [74], although the time lag before any benefits
from screening can be expected [75], together with the
reduction in mortality resulting from notable advances in
treatment (see below), makes quantification of the
contribution of each problematic. One of the indirect
beneficial effects of screening might have been a shift
towards earlier diagnosis of breast cancer, as a result of
the publicity surrounding the disease and its prevention.
The role of treatment and management
Reductions in mortality before the introduction of
screening, and in those countries without screening
activity, indicate that several improvements in disease
management might explain many of the observed declines
in mortality [75,76]. In the UK [9] and Finland [71], the
rapid decline in mortality rates shortly after implementation
of screening programmes was probably due in part to an
increased use of tamoxifen among postmenopausal
women with node-positive disease. The Early Breast
Cancer Trialists’ Cooperative Group reported in a meta-
analysis of 55 randomised adjuvant trials that tamoxifen
reduced the incidence of contralateral breast cancers by
47% at 5 years [77]. It is likely that the increasing use of
this anti-oestrogen has contributed to decreases in
mortality from breast cancer in women who are positive for
oestrogen receptor in developed countries during the
1990s [78]. However, it has been suggested that the
absolute benefit is more modest [79], because most trials
reported on oestrogen receptor-positive women with early
disease, whereas about one-third of women are negative
for the oestrogen receptor, and many women with breast
cancer do not present with early stage disease.
A likely contributory factor to the decline, as noted in the
UK, has been the establishment of treatment protocols,
improved chemotherapeutic options and better thera-
peutic guidelines [74]. Specific structural changes that
have embraced specialisation of breast cancer care (such
as centralised treatment, adjustments in clinician work-
load, and use of multidisciplinary teams) have been shown
to improve outcome [80].
Preventive strategies in the future
The primary risk factors for breast cancer are not easily
modifiable because they stem from prolonged
endogenous hormonal exposures. The beneficial impact
on breast cancer mortality from wider implementation of
screening and continuing improvements in treatment are
likely to accrue. Primary prevention strategies aimed at
promoting breastfeeding, particularly in relation to
duration, might also be beneficial [81].
Prevention trials have shown that tamoxifen lowers breast
cancer incidence by 30–40% in high-risk women [82].
Currently, it is the only agent to have general approval for
chemoprevention of breast carcinoma. However, as
tamoxifen and raloxifene raise the risk of thromboembolic
disease and endometrial cancer about twofold, different
strategies are being pursued to improve the risk : benefit
ratio of chemoprevention. Several ongoing trials are
investigating a range of preventive regimes, with
considerable interest in the aromatase inhibitors [83].
Further study is necessary to determine which genes
consistently predict known breast cancer risk factors, to
be able to screen for these and implement prevention
[84]. Surgical intervention should largely be limited to
those women who have a mutation in BRCA1 or BRCA2.
Mastectomy has already been chosen by some women
who have these mutations, and it can be taken that the
number opting for this therapy will increase [85].
Of crucial importance is access to breast cancer care, its
extent of coverage, and the particular modalities of such
care. This includes interventions that target deprived
societal groups and, critically in developing regions of the
world, the provision and extension of these services to
counter the increasing rates of breast cancer observed in
most developing countries.
Conclusions
Despite much research directed at understanding and
controlling breast cancer, it persists as a major health
burden. The interpretation of breast cancer incidence and
mortality patterns are complex in view of the numerous
and interactive known and putative risk determinants, the
introduction of screening and the substantial
improvements in therapy. It is therefore likely that the
descriptive epidemiology of breast cancer will continue to
provide insights into the complex causation of this
important disease and will allude to the role of primary
prevention, early diagnosis and treatment.
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